FANJ
KERX

Financial Architects (New Jersey)’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Financial Architects (New Jersey)’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-282
Closed -$1K – 1571
2018
Q3 		$1K Hold
282
– – ﹤0.01% 1400
2018
Q2 		$1K Hold
282
– – ﹤0.01% 1309
2018
Q1 		$1K Hold
282
– – ﹤0.01% 1375
2017
Q4 		$1K Hold
282
– – ﹤0.01% 1467
2017
Q3 		$2K Hold
282
– – ﹤0.01% 1434
2017
Q2 		$2K Hold
282
– – ﹤0.01% 1461
2017
Q1 		$2K Hold
282
– – ﹤0.01% 1491
2016
Q4 		$2K Hold
282
– – ﹤0.01% 1321
2016
Q3 		$1K Hold
282
– – ﹤0.01% 1436
2016
Q2 		$2K Buy
+282
New +$1.58K ﹤0.01% 1368
2015
Q3 		– Sell
-127
Closed -$1K – 1083
2015
Q2 		$1K Buy
+127
New +$1.36K ﹤0.01% 1204

Financial Architects (New Jersey)'s KERX Position: Q4 2018 in Review

Financial Architects (New Jersey) sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 282 shares — an estimated $1K sold.

Financial Architects (New Jersey) first reported a position in KERX in Q2 2015 and held it in 11 quarters. The position peaked at $2K in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Financial Architects (New Jersey) reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 282 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $1K.
  • Financial Architects (New Jersey) first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 11 quarters.
  • Financial Architects (New Jersey)'s Keryx Biopharmaceuticals Inc position peaked at $2K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2018, filed 1 Feb 2019.